Dronedarone warning
January 24, 2011
THE UK Medicines and
Healthcare products Regulatory
Agency (MHRA) has published new
information on the possible risk of
liver injury associated with
Dronedarone (Multaq).
Dronedarone is indicated in
adult clinically stable patients with
a history of, or current nonpermanent,
atrial fibrillation (AF)
to prevent recurrence of AF, or to
lower ventricular rate.
The warning follows the
reportage of several cases of liver
injury (some of which occurred
early after the start of treatment),
including two cases of liver failure
requiring transplantation.
As a result, the MHRA is
advising healthcare professionals
that patients currently using the
drug should be contacted over the
next month to receive liver function
tests, to be followed up with
routine liver testing
The MHRA is also urging
patients taking Dronedarone and
who experience any symptoms of
liver injury to contact their
healthcare professional.
Patients concerned about their
treatment are being urged to
consult their doctor before ceasing
usage of the drug.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jan 11To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jan 11
